US EditionBooster for cellular immunotherapy: Immunologist Michel Sadelain awarded Meyenburg Prize - German Cancer Research CenterLogo des Deutschen KrebsforschungszentrumsLogo of the German Cancer Research CenterLogo of the German Centers for Health ResearchLogo o
Summary by dkfz.de
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Booster for cellular immunotherapy: Immunologist Michel Sadelain awarded Meyenburg Prize - German Cancer Research CenterLogo des Deutschen KrebsforschungszentrumsLogo of the German Cancer Research CenterLogo of the German Centers for Health ResearchLogo o
In 2017, the US Food and Drug Administration (FDA) granted approval for the first time for a completely new treatment for blood cancer in children who could no longer be treated with chemotherapy: they received immunotherapy with their own genetically modified T cells, so-called CAR-T cells. In most patients, the disease responded very well to the treatment – and in many cases, the therapeutic success was permanent, lasting for many years. There
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
